BioWorld

July 17, 2008

View Archived Issues

MacroGenics Boosts Anticancer Pipeline with Raven Acquisition

In a deal to be announced Thursday morning, MacroGenics Inc. is bolstering its anticancer antibody pipeline with the acquisition of Raven Biotechnologies Inc. (BioWorld Today) Read More

Optimer's Prulifloxacin Data Positive in First Phase III Study

Read More

Same Receptor is Helpful, Harmful for HIV Infection

Read More

BioAlliance Stops Doxorubicin Trial After Pulmonary Reactions

Read More

Jazz $26M Stock Sale to Fund Luvox Commercialization

Read More

PTC Gets $25M From Nonprofit to Fund Cystic Fibrosis Studies

Read More

Other News To Note

Read More

Clinic Roundup

Read More